ALX Oncology Holdings ALXO 深 沪
已收盘 07-02 16:00:00 美东时间
2.07
+0.010
+0.49%
华盛通- 最 高2.125
- 今 开2.08
- 成交量 106.74万股
- 最 低 2.015
- 昨 收 2.06
- 总市值 2.79亿
- 52周最高 2.66
- 市盈率 静 --
- 换手率 0.79%
- 52周最低 0.444
- 委 比 -15.83%
- 总股本 1.35亿
- 历史最高 117.45
- 量 比 0.27
- 振 幅 5.34%
- 历史最低 0.404
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ALX Oncology Appoints New Chairman Amid Leadership Changes
The latest announcement is out from ALX Oncology Holdings ( ($ALXO) ). On June ...
07-01 04:39
ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the appointments of Scott Garland as Chairman of the Board of Directors (the "Board") and Mic...
06-30 20:12
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
ALX Oncology Holdings Inc. announced that its leadership will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 5:30 PM ET. The webcast can be accessed via their website or the provided link. ALX Oncology focuses on developing innovative cancer therapies, with its lead candidate, evorpacept, and ALX2004, an EGFR-targeted antibody-drug conjugate, currently in clinical trials.
06-01 12:00
ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 68.75 percent increase over losses of $(0.48) per share
05-08 20:02
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported positive data from its Phase 1b/2 trial of evorpacept combined with zanidatamab in HER2-positive breast cancer patients, showing durable responses, particularly in those with high CD47 expression. The company also highlighted progress in its ASPEN-09-Breast Phase 2 trial and ALX2004 Phase 1 trial. Additionally, ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer, strengthening its leadership team. T...
05-08 12:00
ALX Oncology To Present New Data From Phase 1b/2 Clinical Trial Evaluating Investigational CD47-Inhibitor Evorpacept In Combination With Jazz's Zanidatamab In HER2-Positive mBC At ESMO Breast Cancer 2026 Congress
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 -SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a
04-30 20:06
ALX Oncology announces annual shareholder meeting webcast
ALX Oncology announces annual shareholder meeting webcast ALX Oncology annual shareholder meeting set for June 10, 2026 in virtual format. Shareholders will vote on election of three Class III directors to serve through 2029. Ballot also includes advisory vote on named executive officer compensation
04-23 12:50
ALX Oncology publishes 2025 annual report
ALX Oncology publishes 2025 annual report ALX Oncology annual report for fiscal 2025 highlighted continued focus on two clinical-stage programs, CD47 blocker evorpacept, EGFR-targeted ADC ALX2004. Evorpacept strategy shifted toward combinations with Fc-active anti-cancer antibodies to drive antibody
04-23 10:55
ALX Oncology Appoints Jeff Knight to Lead Development
ALX Oncology Holdings ( ($ALXO) ) has shared an update. On April 13, 2026, ALX ...
04-13 20:58
